News in Brief

Published: 1-Mar-2003


  • Bristol-Myers Squibb has agreed to pay US$670m (€626m) to settle numerous lawsuits after it was accused of using illegal tactics to keep lower-priced versions of its medicines, cancer-fighting Taxol and the anti-anxiety drug BuSpar, out of the market for many months. Both drugs are now available as generic medicines.

  • The EU has initiated formal talks ; the first stage of disputes proceedings at the World Trade Organisation ; over import restrictions imposed by the Indian government on a range or products including penicillin, its salts, and derivatives, rifampicin, streptomycins or their derivatives, and first aid boxes or kits.

  • The European Agency for the Evaluation of Medicinal Products (EMEA) has announced that the EU marketing authorisation for hepatitis B treatment Hepacare has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals' commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.

  • An EU-funded research project has identified four strains of lactobacilli that could help treat intestinal inflammations and infections. The aim of the Deprohealth scheme, which has received €1.4m ($1.5m) in Brussels money; is to develop oral probiotic bacteria vaccines to counter conditions such as rotavirus, which causes infant diarrhoea, and Crohn's disease. Participating researchers from France, Italy, Belgium, Spain, the UK and Australia have had to identify strains that not only prevented inflammation, but also could withstand human digestive acids.

  • A US federal judge has ruled that an approval letter with a delayed effective date given by the FDA should be considered merely a tentative approval and does not give a manufacturer the legal right to begin marketing a medicine. The judge was ruling against Barr Laboratories' bid to market a generic version of tamoxifen tablets, which the company had expected to release last August. He quashed a bid by Barr to overturn FDA restrictions on selling a product ahead of its release. The FDA had stressed that Barr should wait until the original patent currently held by AstraZeneca had expired.
    See more

    • You may also like

    Medical Devices

    Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

    Read more
    A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies

    Trending Articles

    1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
    2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
    3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
    4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
    5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

    Upcoming event

    Enhancing probiotic stability through smarter formulation and packaging strategies

    18 September 2025 | Virtual     See all

    You may also like

    Medical Devices

    Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

    A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
    Manufacturing

    Sapio Sciences introduces world’s first 3rd-generation ELN

    Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
    Manufacturing

    Signal Group launches MCERTS approved VOC emissions monitor

    New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
    Research & Development

    Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

    The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
    You need to be a subscriber to read this article.
    Click here to find out more.
    Packaging

    Cloud labelling and serialisation: the new frontline of traceability in drug delivery

    As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
    Manufacturing

    Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

    The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
    Manufacturing

    L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

    Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
    Subscribe now